Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...